Parabilis Medicines, Inc. (PBLS)
Parabilis Medicines, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $24.44, down 9.21% on the session, giving a market capitalisation of $2.98B. On trailing twelve-month figures it carries a trailing P/E of -0.66, a net margin of -66066.9%. Its beta of 5.03 implies it has historically moved more than the broad market.
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Parabilis Medicines, Inc. is most often compared with the following Healthcare names: